Columbia University researchers have identified a connection between serotonin and the progression of degenerative mitral regurgitation, a condition where the heart's mitral valve fails to close properly. The finding raises questions about antidepressant use in vulnerable patients.
The team discovered that individuals carrying a specific genetic variant who take selective serotonin reuptake inhibitors (SSRIs) may experience accelerated valve deterioration. This subgroup could require surgical intervention earlier than patients without the genetic marker or those not using SSRIs.
Mitral regurgitation affects millions globally, often progressing silently for years before symptoms emerge. Currently, treatment depends on disease severity, ranging from monitoring to valve repair or replacement surgery. The Columbia study adds a pharmacogenetic dimension to disease management that clinicians have not previously considered systematically.
The research examined how serotonin acts on valve tissue itself, not just its well-established role in the brain. The chemical may trigger molecular pathways that promote fibrosis and structural degradation in the valve leaflets, particularly in genetically susceptible individuals. SSRIs work by increasing serotonin availability in the body, potentially amplifying this effect.
The practical implications remain complex. Millions of patients take SSRIs for depression and anxiety without developing heart problems. The Columbia team identified only a subset at elevated risk, defined by their genetic profile. Patients should not stop antidepressants without medical guidance, as the psychiatric benefits typically outweigh the cardiac risk in most cases.
However, the discovery enables more personalized medicine. Genetic screening could identify at-risk patients early, allowing cardiologists to monitor them more closely with echocardiography. For those carrying the variant, alternative antidepressants or different depression management strategies might offer safer options while maintaining mental health treatment.
The research underscores how medications developed for one system can affect